NCT04782895已完成3 期
A Randomized, Single-blind Study to Compare Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) (Xiamen Innovax Biotech Co.,Ltd.) Versus Gardasil®9 (Merck & Co., Inc.) in Healthy Females 18-26 Years of Age
Xiamen University1 个研究点 分布在 1 个国家目标入组 488 人开始时间: 2021年3月14日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 488
- 试验地点
- 1
- 主要终点
- Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing antibody level
研究概览
简要总结
This study is designed to compare the immunogenicity of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females 18-26 Years of Age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 26 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Subject is female, between and including 18-26 years of age at the first vaccination;
- •Subject is able to understand and comply with the requirements of the protocol(e.g. biological specimen collection, completion of the diary cards, return for follow-up visits), and written informed consent must be obtained from the subject prior to enrollment;
- •Subject who agrees to practice effective contraception within 8 months after the first vaccination or has undergone tubal ligation,subtotal hysterectomy for benign lesion, ovarian benign tumor resection;
- •No previous history of sexually transmitted diseases (including syphilis, gonorrhea, chancroid, venereal lymphogranuloma, groin granuloma, etc.);
- •No previous history of abnormal cervical screening results or cervical intraepithelial neoplasia (CIN);
排除标准
- •Axillary temperature > 37.0℃;
- •Subject who has a positive urine pregnancy test, or is pregnant or breastfeeding;
- •Subject has used of any investigational or non-registered product (drug or vaccine) within 30 days preceding the first dose of study vaccine or plans to use during the study period , or has participated in another clinical research in the past two years, or plans to participate in another research during the study period;
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs or systemic corticosteroids (Except intranasal steroid, the use of low dose topical, ophthalmic and inhaled steroid preparations will be permitted.) within 6 months prior to vaccination.
- •Administration of immunoglobulin and/or blood products within 3 months prior to vaccination or planned to use them within 7 months after the first dose.
- •Administration of inactivated vaccine within 14 days prior to vaccination or live vaccine within 21 days;
- •Fever (Axillary temperature ≥38.0℃) 3 days prior to vaccination or system administration of antibiotics or antiviral agents within 5 days prior to vaccination;
- •Subject has received other HPV vaccines or participated in clinical research related to HPV or cervical cancer previously;
- •Subject has immunodeficiency disease, primary disease of important viscera, cancer and autoimmune disease (including systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy due to any condition, and other immunological diseases that investigators believe may influence the immune response).
- •History of severe allergy (e.g., anaphylaxis, generalized urticaria, dyspnea, angioedema, and other significant reaction) to any previous vaccination, or be allergic to any of the components of the study vaccines.
- •Asthma, which has been unstable for the past two years and requires emergency treatment, hospitalization, oral or intravenous corticosteroids;
- •Subject has Serious medical disorders;
- •Self-report coagulation disorders or abnormal coagulation function;
- •Epilepsy, excluding febrile epilepsy under 2 years of age, alcoholic epilepsy 3 years prior to abstinence or simple epilepsy that does not require treatment in the past 3 years;
- •Medical, psychological, social conditions, occupation or other factors, which considered by the investigator that may influence the conduct of the clinical study.
结局指标
主要结局
Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing antibody level
时间窗: 7 months after the first dose
Anti-HPV 6,11,16,18,31,33,45,52 and 58 seroconversion rates and geometric mean concentrations at months 7
次要结局
- safety2:Adverse events/reactions occurred within 30 days after each vaccination.(Within 30 days (Day 0-30) after any vaccination)
- safety3:Severe adverse events occurred throughout the study. To evaluate number of SAEs compared with the control vaccine.(Up to 8 month)
- safety4:Pregnancy and pregnancy outcome. To evaluate number of births and terminations compared with the control vaccine.(Up to 8 month)
- safety1:Local and systematic adverse events/reactions occurred within 7 days after each vaccination.(During the 7-day period following each vaccination)
研究者
Jun Zhang
professor
Xiamen University
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy FemalesHuman PapillomavirusNCT01548118Shanghai Zerun Biotechnology Co.,Ltd160
已完成
3 期
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) PatientsChronic Kidney DiseaseNCT00985426Dynavax Technologies Corporation521
已完成
3 期
Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) VaccinationCervical CancerNCT00964210Murdoch Childrens Research Institute240
已完成
1 期
A Phase I Study of Quadrivalent HPV Recombinant VaccineHPV InfectionsNCT03085381Shanghai Bovax Biotechnology Co., Ltd.90
已完成
3 期
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCervical CancerVaginal CancerCIN1CIN2CIN3VaIN1VaIN2VaIN3Genital WartVIN 1VIN 2VIN 3AISVulvar CancerNCT04425291Shanghai Bovax Biotechnology Co., Ltd.1,680